Date: 2012-01-10
Type of information: Licensing agreement
Compound: IDH1/IDH2 biomarker
Company: Qiagen (The Netherlands) Ipsogen (France) Personal Genome Diagnostics (USA)
Therapeutic area: Cancer Oncology
Type agreement:
Action mechanism:
Disease: brain cancers, acute myelogenous leukemia (AML) and certain other malignancies
Details: Through an agreement between its 89% subsidiary Ipsogen and Personal Genome Diagnostics Inc., of Baltimore, Maryland, Qiagen has acquired worldwide exclusive rights to testing for mutations of the IDH1 and IDH2 genes – which are believed to play a role in brain cancers, acute myelogenous leukemia (AML) and certain other malignancies.
Financial terms: Financial terms were not disclosed.
Latest news:
